Healio compiles top pediatric dermatology articles of 2024

Key takeaways:

• A study finding endocrine-disrupting chemicals in children using certain personal care products topped the list.
• An article detailing the CDC’s guidelines on lice management followed.

As 2024 comes to a close, Healio has assembled this year’s most-read pediatric dermatology articles.

The top stories include a study on endocrine-disrupting chemicals in personal care products, CDC guidance on lice, boxed warnings and more:

Endocrine-disrupting chemicals from personal care products found in young children

The use of personal care products, including lotions, oils and others, was associated with endocrine-disrupting chemicals called phthalates in children aged as young as 4 years. Michael S. Bloom, PhD, professor in the department of global and community health at the College of Public Health at George Mason University, discussed this finding with Healio. Read more.

No changes to CDC guidelines recommending children with lice do not need to leave school

Despite popular news outlets reporting the opposite, the CDC did not change its guidelines this year on how to respond when a child in school presents with lice. After speaking with Danilo Del Campo, MD, FAAD, a dermatologist at the Chicago Skin Clinic, Healio found that the CDC still recommends children with lice do not need to be sent home early from school. Read more.

‘With great power comes great responsibility’: Boxed warnings in pediatric dermatology

According to a speaker at South Beach Symposium, pediatric dermatologists should be open with patients and families when discussing boxed warnings while emphasizing that the benefits outweigh the risks. Read more.

Education reduces concerns, improves outcomes for children using topical corticosteroids

Video education about topical corticosteroids alleviated caregivers’ concerns and improved outcomes for pediatric patients with eczematous dermatitis. Read more.

High propranolol initiation dose well tolerated in infantile hemangioma

A study found that initiating infantile hemangioma treatment with propranolol 2 mg/kg per day did not yield more adverse events than 1 mg/kg per day. Read more.

Mass ivermectin administration reduces scabies, impetigo

Scabies and impetigo prevalence was reduced significantly with mass administration of ivermectin or permethrin in small Indian communities, according to a study. Read more.

FDA grants rare pediatric disease designation to Descartes-08 for juvenile dermatomyositis

On Sept. 9, 2024, the FDA granted rare pediatric disease designation to Descartes-08, an autologous mRNA cell therapy, for the treatment of juvenile dermatomyositis. Read more.

Apremilast efficacious in pediatric psoriasis

Pediatric patients with psoriasis experienced significant improvement with oral apremilast treatment. Read more.

Q&A: Dermatologists can provide valuable experiences for young patients at Camp Discovery

Since 1993, the American Academy of Dermatology has held a unique weeklong summer camp experience for kids aged 8 to 16 years with chronic skin conditions. Healio spoke with Seemal R. Desai, MD, FAAD, president of the AAD, about the benefits of this experience. Read more.

Beneath the Surface: Investigating dupilumab’s use in pediatric alopecia areata treatment

In this edition of Beneath the Surface, a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts, Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology and director of the Center of Excellence in Eczema and the Laboratory of Inflammatory Skin Diseases at Icahn School of Medicine at Mount Sinai, discussed the ongoing research regarding the use of dupilumab as a treatment for alopecia areata in children. Read more.